Kornimate/medical-research-clean huggingface dataset:
intervention to prevent mental health disorders of women and their partners who experienced pregnancy loss

Conditions: Stillbirth and Fetal Death

Summary: the goal of this clinical trial is to test impact of a multiprofessional intervention in mothers and partners who suffer a pregnancy loss. the main questions it aims to answer are: * impact on mothers and partners mental heatlht status * reasons why mothers do not consent to the intervention participants will: * mothers and partners will complete 4 scales * mothers and partners will participate in a interview researchers will compare with mothers with standard care to see if the multiprofessional intervention has an impact.

objective 1: evaluate the effectiveness of the multi professional intervention to reduce the intensity of grief, depression, anxiety and ptsd symptoms in women and their partners after pregnancy loss. objective 2: assess the extent to which the multiprofessional intervention was implemented as intended (fidelity) and understand how the intervention becomes integrated into routine healthcare practice (implementation).

Eligibility criteria:
inclusion criteria: * women and their partners who suffer a pregnancy loss * health professionals who have worked for at least 1 year in the hospital studied exclusion criteria: * participants who do not understand spanish/catalan
effect of remimazolam on motor evoked potential

Conditions: Spine Disease

Summary: this study was planned to investigate the degree of effect of remimazolam on mep compared to propofol when monitoring the motion-inducing potential (mep).


Eligibility criteria:
inclusion criteria: * aged 20-70 * scheduled for elective spine surgery requiring monitoring of evoked potential * asa physical status 1-3 exclusion criteria: * bmi ≥ 40 * uncontrolled dm (hba1c ≥ 9%) * contraindications to the study drug: known allergy or hypersensitivity * use of rate responsive cardiac pacemaker with bioelectrical impedence * diagnosed neuromuscular disorder * pre-existing motor weakness
study of 5-fu + leucovorin + cpt-11 in patients with resectable liver metastases from colorectal adenocarcinoma

Conditions: Colorectal Adenocarcinoma; Liver Metastases

Summary: when colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. however, the cancer has a chance or reoccurring in the liver or elsewhere in the body. this study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

when colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. however, the cancer has a chance or reoccurring in the liver or elsewhere in the body. this study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Eligibility criteria:
inclusion criteria: * stage iv colorectal cancer isolated to the liver * one measurable lesion * metastases are completely resectable or amenable to ablation * karnofsky \>70 * adequate bone marrow function * adequate hepatic function * adequate renal function * informed consent exclusion criteria: * primary tumor not controlled by locoregional treatments * bilateral portal vein and/or hepatic artery involvement * previous chemotherapy directed at treatment of metastatic colorectal cancer * underlying acute or chronic liver disease * gilbert's disease * patients receiving phenytoin or phenobarbital prophylaxis * presence of any concurrent medical or psychiatric condition that serves as a contraindication to surgery or chemotherapy * pregnancy * malignancy other than basal cell or squamous cell carcinoma of the skin within the preceding 5 years * use of another investigational medication concurrently or within 4 months of enrollment

Keywords: resectable liver metastases colorectal adenocarcinoma survival neoadjuvant chemotherapy
comparison of direct anterior and posterior surgical approaches in regards to the patient' physical characteristics

Conditions: Hip Arthropathy

Summary: recent increased interest in tissue-sparing and minimally invasive arthroplasty has given rise to a sharp increase in the utilization of direct anterior total hip arthroplasty.

* purpose: the direct anterior approach to the hip has been suggested to have several advantages compared to previously classical approaches. however, no studies focused on the effects of these different surgeries on patients' perception recovery and walking efficiency according the initial physical fitness. therefore, the purpose of this study is to compare the effects of surgical procedures on perceptual walking skills and efficiency according to the patients' physical fitness. * abstract : some earlier studies report differences between surgery types in self- reported mobility, functional recovery and residual hip pain. the direct anterior approach to the hip has been suggested to have several advantages compared to previously popular approaches through its use of an intra-muscular and intra-nervous interval between the tensor fasciae latae and sartorius muscles. however, patients' physical fitness, postural response and perceptual walking skill relation was not taking account. 80 patients will be tested, one before and at various times after hip surgery. in randomized conditions, our patients will be divided in two groups, according the surgery approaches and their physical fitness. all patients performed a performance-oriented mobility assessment walking test with and without step and the pma, harris, oxford 12 and womac scores will be evaluated before, 3 weeks, 6 weeks, 3 months and 1 year after the surgery. during the performance-oriented mobility assessment walking test, self-reported walking capacity, rating of exertion perception and walking parameters will be measured.

Eligibility criteria:
inclusion criteria: * age \> 50 years * body mass index \< 35 * scheduled hip arthroplasty surgery * exclusion criteria: * no health coverage * age \> 85 years * body mass index ≥ 35 * cognitive impairment (score mini mental statue \< 24) * any other osteo-articular diseases than the operated hip, any muscular or neurological diseases that could penalize the walk

Keywords: hip arthroplasty surgeries physical fitness perception energetic cost autonomy
upnride powered wheelchair for individuals with walking impairment: evaluation of safety and usability

Conditions: Spinal Cord Injury Cervical

Summary: the upnride powered wheelchair device is a product which changes people position from sitting to standing and standing to sitting. the product provides indoor and outdoor mobility. the main purpose of this study is to evaluate the safety of the upnride powered wheelchair as an outdoor and indoor mobility device by individuals with walking impairment.

a new powered wheelchair has recently been developed to address the ability of the user to be able to position them in an upright, standing position. this new device is called the upnride powered wheelchair and is different from other upright wheelchairs because current standing wheelchair models have limited mobility in the standing position. the upnride is an upright or seated mobility device that is intended to provide full upright standing posture in a mobile powered wheelchair. the upnride powered wheelchair provides wheelchair and scooter users the ability to engage in society in either a standing (upright mobility) or seated position (seated mobility). additionally, the option to have upright posture throughout the day may have the potential to improve some of the secondary medical conditions associated with the extreme sedentary lifestyle that paralysis from sci imposes. this wheeled, motorized device can provide mobility to most urban environment situations by being able to be navigated indoors and outdoors and over different surfaces in both the standing or seated positions.

Eligibility criteria:
inclusion criteria 1. males and non-pregnant, non-lactating females 2. ages 18-70 3. suffered from a sci which caused tetraplegia, asia a-b-c 4. at least 1 year after sci 5. height of 155 to 190 cm; 6. weight less than 100 kg 7. able to sign informed consent. 8. power or manual wheelchair user as a primary means of mobility 9. regular user of a standing frame or tilt table for at least 30 minutes a week exclusion criteria 1. history of severe neurological disorder other than sci (multiple sclerosis, cerebral palsy, amyotrophic lateral sclerosis, traumatic brain injury, stroke, etc.) 2. concurrent severe medical disease 3. pressure sores 4. unstable spine 5. unhealed limb or pelvic fractures 6. psychiatric or cognitive status that may interfere with the trial
extended versus limited thoracoscopic sympathectomy: its impact on palmar and plantar hyperhidrosis

Conditions: Hyperhidrosis Due to Autonomic Dysregulation (Disorder)

Summary: conclusions: in the context of palmar and plantar hyperhidrosis, extended thoracoscopic sympathectomy seemed to be preferred over limited thoracoscopic sympathectomy due to better overall outcomes and minimal time for hospital stays and compensatory hyperhidrosis.

abstract objective: the aim was to carefully evaluate and compare the results of extended sympathectomy versus t3, t4, and t5 resection in cases of palmer, axillary, and planter hyperhidrosis as regards decreased sweating and recurrence rates. methods: this was a randomized controlled prospective trial conducted at the department of vascular surgery mansoura university hospitals on a total of 120 patients with hyperhidrosis who were divided into two groups; group 1 who had undergone limited sympathectomy and group 2 who had undergone extended sympathectomy.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hyperhydrosis * able to take drugs * palmer and planter hyperhydrosis * age from 6-24 years * interfere with daily activities exclusion criteria: * not fit for surgery * thyroid disease * age less than 6 years * chest or cardiac problems
rosiglitazone versus placebo in chronic stable angina

Conditions: Angina Pectoris; Metabolic Syndrome X

Summary: we wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not have overt diabetes. the drug will be given for 3 months and the subjects will be have their angina tested, by way of exercise testing, angina quality of life questionnaire and 24-hour ecg monitoring before and after using the drug.

chronic stable angina is a common manifestation of ischaemic heart disease. current mechanical therapies (percutaneous coronary intervention and coronary artery bypass grafting) and pharmacological therapies (nitrates, calcium channel blockers, betablockers and potassium channel activators) main actions are to treat the end product of ischaemic heart disease on chronic stable angina, i.e. the flow limiting stenosis. we postulate that by treating insulin resistance, an upstream factor in the pathogenesis of ischaemic heart disease, we will improve angina by in turn improving endothelial function. we will attempt to demonstrate this by way of full bruce protocol exercise tolerance test, seattle angina questionnaire and 24 hour st segment analysis before and after treatment with the insulin sensitiser rosiglitazone for three months.

Eligibility criteria:
inclusion criteria: * chronic stable angina - to see if this improves * previous positive exercise tolerance test - to ensure that repeating it yields a result * disease not suitable for coronary intervention (coronary artery bypass grafting or angioplasty) - so that best routine care is not withheld * do not have overt diabetes - work on this is being undertaken elsewhere * body mass index (bmi) greater than 25 exclusion criteria: * diabetes mellitus - see above * liver failure (alt\>70u/l, ast\>80u/l) * renal failure (creatinine \> 130mmol/l) * cardiac failure - rosiglitazone is contraindicated in those with nyha 3 and 4 cardiac failure * physical disability - if it precludes treadmill testing * women of child bearing capacity * breast feeding mothers

Keywords: angina pectoris metabolic syndrome ischaemic heart disease
a prospective, randomized trial comparing office-based mr-guided prostate biopsy approaches

Conditions: Prostate Cancer; Elevated PSA

Summary: this randomized trial will compare the safety and efficacy of tpm versus trus biopsies performed in the outpatient setting. primary endpoints will be pain as well as detection of clinically significant disease (defined as gleason score \>=7 or cancer core length \>=6 mm). secondary endpoints will be detection of any prostate cancer, hospital re-admissions within 30 days, aborted procedures due to discomfort, procedure time, adverse events including hematuria, urinary retention, hematospermia, hematochezia, and infection, and patient-reported outcomes as measured on validated instruments such as international prostate symptom scores (ipss) and international index of erectile function (iief-5). in men who subsequently elect to undergo radical prostatectomy for definitive treatment of their prostate cancer, gleason scores at final pathology will be correlated to the gleason scores obtained at time of biopsy.

the feasibility of outpatient tpm has been well demonstrated.(bianco \& martínez-salamanca, 2016; merrick et al., 2016; smith et al., 2014) new technology now allows for fusion of mri images with tpm devices, allowing for targeting of cancerous-appearing lesions on mri. such technology that fuses mri-imaging with trus biopsy has become routine in u.s. clinical practice, with improved cancer detection rates as compared with standard trus.(ahmed et al., 2017; robertson, emberton, \& moore, 2013) this randomized trial will compare the safety and efficacy of tpm versus trus biopsies performed in the outpatient setting. men will be randomized to receiving either tpm or trus targeted biopsy. all men will receive a urine culture within 2 weeks of biopsy and will be started on antibiotic prophylaxis prior to biopsy in accordance with aua antimicrobial prophylaxis guidelines. men with a positive urine culture will be treated with culture-specific antibiotics and must have a documented negative urine culture prior to biopsy.

Eligibility criteria:
inclusion criteria: * men 18 years or older with suspicion for prostate cancer based upon an elevated psa, abnormal digital rectal examination, abnormal mri * men on active surveillance with indication for biopsy exclusion criteria: * men with active urinary tract infection, metastatic prostate cancer, history of colorectal surgery limiting insertion of transrectal probe, evidence of acute or chronic prostatitis, or concern for perineal cellulitis or fistula * men unfit to undergo prostate biopsy under local anesthesia * men with prior definitive therapy for prostate cancer, such as radiation therapy or partial gland ablation * men with contraindication to prostate mri (claustrophobia, pacemaker, chronic kidney disease)
ibuprofen iv vs acetaminophen iv for the treatment of pain following orthopaedic low extremity surgery

Conditions: Lower Extremity Problem; Surgery; Postoperative Pain

Summary: this study aims to evaluate the efficacy of iv ibuprofen versus iv acetaminophen in the reduction of pain following orthopedic low extremity procedures

approval from ethical committee of faculty of medicine universitas indonesia was acquired prior conducting the study. patients undergoing orthopedic low extremity surgery were screened. eligible subjects were then randomized into treatment group (intravenous ibuprofen) and control group (intravenous acetaminophen). in case required, patients from both group will be given morphine (pca) 1-2 mg every 5 minutes.

Eligibility criteria:
inclusion criteria: * scheduled for orthopedic low extremity surgery with general anesthesia and anticipated need post operative iv analgesia with anticipated use of \>48 hours. * adequate iv access. * anticipated hospital stay\>48 hours. * age 18-70 years old with physical status asa i- iii. * patients able to fill informed consent sheet. exclusion criteria: * patients with use of analgesia, muscle relaxants, nsaids and sedatives less than 24 hours to study drug administration * anemia (active, clinically significant anemia) and/or a history or evidence of asthma or heart failure * historical or at higher risk intracerebral bleeding, history of allergy or hypersensitive to nsaid, ibuprofen, acetaminophen or opioid * pregnant or nursing * body weight less than 30 kg * any active clinically significant bleeding or have underlying platelet dysfunction and/or receiving full dose anticoagulation therapy * gi bleeding that required medical intervention within the previous 6 weeks (unless definitive surgery has been performed) * on dialysis or renal dysfunction * impaired liver function * inability to achieve hemostasis or inability to close surgical incision prior to operating room discharge * operative procedure includes organ transplant, pre-and intra- operative procedure utilized for the prevention of pre- or post-operative pain (i.e, epidural or nerve blocks) * received anoher investigational drug within the past 30 days * known or suspected history of alcohol or drug abuse * severe infection and/or inflammatory disease

Keywords: ibuprofen acetaminophen orthopedic vas morphine opioid
effect of high altitude exposure, acclimatization and re-exposure on cerebral autoregulation in lowlanders

Conditions: Effect of High Altitude

Summary: prospective interventional trial in lowlanders evaluating the effect of acute exposure, acclimatization and re-exposure to high altitude on cerebral autoregulation

baseline measurements will be performed in santiago de chile, 520 m, over the course of 3 days. participants will then travel by commercial airline (5 h flight) and by bus (3 h ride) to the alma base camp located at 2900 m near san pedro de atacama, northern chile. participants will stay there for the next 8 nights and they will be spend the days (6-8 h daily) at the telescope station at 5050 m while undergoing testing as described above at the first and the last day at 5050m. daily transports from 2900 to 5050 m will be by car (1 h ride, one way). after the first 8 day altitude sojourn participants will return to the santiago area (520 m) for a 6 day recovery period. a second altitude sojourn with an identical schedule as the one described above and a final low altitude stay of 3 days will follow.

Eligibility criteria:
inclusion criteria: * born, raised and currently living \<800m * no overnight stay at altitudes \>1500 m 4 weeks before the study exclusion criteria: * previous altitude intolerance to altitude \<3000 m * pregnancy * health impairment, which requires regular treatment

Keywords: high altitude cerebral autoregulation transfer function analysis
dose ranging study of pazopanib to treat neovascular age-related macular degeneration

Conditions: Macular Degeneration

Summary: the purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.

md7110852 is a phase 2b dose-ranging study designed to demonstrate the 1 year efficacy and safety of pazopanib eye drops for the treatment of neovascular age related macular degeneration (amd) in subjects whose disease is currently managed with anti-vegf (vascular endothelial growth factor) injection therapy. eye drop regimens are double-masked with placebo eye drops and will have access to open-label ranibizumab intravitreal (ivt) injection if needed. the ranibizumab ivt injection every 4 weeks control arm is open-label.

Eligibility criteria:
inclusion criteria: * men and women aged ≥50 years. * active subfoveal choroidal neovascularization (cnv) lesion secondary to amd in study eye: total lesion area ≤12 disc areas with cnv ≥50% total lesion area. * anti-vascular endothelial growth factor (vegf) intravitreal injection experienced and in need of re-treatment. * best-corrected visual acuity of at least 24 letters (equates to approximately 20/320 snellen equivalents or better). exclusion criteria: * prior ocular investigational drug/device for choroidal neovascularization, photodynamic therapy, radiation, subfoveal or juxtafoveal focal laser photocoagulation. * prior failure to anti-vegf intravitreal injection therapy. * recent ocular investigational drug/device for non-cnv condition. * prior ocular surgeries (vitrectomy, scleral buckle, or glaucoma filtering/shunt surgery). cataract surgery permitted if ≥3 months and has posterior chamber intraocular lens. * center-fovea involvement of any of the following: fibrosis, atrophy, serous retinal pigment epithelial detachment, or retinal pigment epithelial tear. * cnv in either eye due to other causes. * clinical evidence of diabetic retinopathy or diabetic macular edema. * recent myocardial infarction or cerebrovascular accident. * uncontrolled hypertension in spite of antihypertensive medications.

Keywords: ranibizumab wet amd md7110852 age related macular degeneration age-related macular degeneration macular degeneration pazopanib
periodontal disease and p. gingivalis in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Osteoarthritis; Periodontal Disease

Summary: periodontitis (pd) has been postulated to be a risk factor for the onset and progression of rheumatoid arthritis (ra). recent reports suggest that infection with porphyromonas gingivalis (p. gingivalis), a major oral pathogen in pd, could play a pivotal role in the development ra. the objective of this study is to examine the relationship of pd and p. gingivalis infection with the risk and severity of ra.

in this study, we will examine whether periodontitis (pd) and p. gingivalis impact rheumatoid arthritis (ra) risk by enrolling 300 patients with ra and 300 comparator patients with osteoarthritis and comparing results from comprehensive dental examinations and antibody responses to p. gingivalis. we will examine whether these associations are modified by the presence of certain genetic risk factors previously implicated in ra and whether evidence of infection with p. gingivalis precedes ra onset by examining banked sera from the department of defense serum repository (dodsr) and the studies of the etiology of ra (sera). we also plan to explore whether there are novel proteins expressed by p. gingivalis that drive autoimmunity in ra and whether immune responses to these bacterial proteins predict the future development of ra.

Eligibility criteria:
inclusion criteria: * age 19 years or older * diagnosis of rheumatoid arthritis, or osteoarthritis * have 9 or more evaluable posterior teeth (out of a total of 28 teeth, excluding third molars) * willing and able to provide informed consent exclusion criteria: * received tetracyclines within the last 6 months. * need for antibiotic premedication for dental probing. * pregnant or breast feeding

Keywords: rheumatoid arthritis osteoarthritis periodontal disease